Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

DAIICHI SANKYO, INC.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate

Phase 1

Recruiting

Conditions: Healthy Subjects

Interventions: Drug: Quizartinib
Other: Placebo

First Posted Date: 2025-01-13

Last Posted Date: 2025-01-13

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 70

Registration Number: NCT06772246

Locations: 🇺🇸
WCT, San Antonio, Texas, United States

Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Quizartinib
Drug: Rufinamide

First Posted Date: 2024-12-18

Last Posted Date: 2024-12-18

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 32

Registration Number: NCT06740825

Locations: 🇺🇸
WCT, San Antonio, Texas, United States

Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment

Phase 1

Recruiting

Conditions: Hepatic Impairment

Interventions: Drug: Quizartinib

First Posted Date: 2024-12-18

Last Posted Date: 2024-12-18

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 12

Registration Number: NCT06740799

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸
Advanced Pharma, Miami, Florida, United States
🇺🇸
GCP Research, Saint Petersburg, Florida, United States

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Phase 3

Recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Trastuzumab Deruxtecan
Drug: pembrolizumab
Drug: Trastuzumab
Drug: Chemotherapy

First Posted Date: 2024-12-12

Last Posted Date: 2025-06-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 726

Registration Number: NCT06731478

Locations: 🇨🇦
Cité de la Santé de Laval, Laval, Canada
🇨🇦
Mount Sinai Hospital, Toronto, Canada
🇨🇳
Beijing Cancer Hospital, Beijing, China

and more 28 locations

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer

Completed

Conditions: Advanced/Metastatic NSCLC
Advanced/Metastatic HER2-negative Breast Cancer

First Posted Date: 2024-11-13

Last Posted Date: 2025-03-19

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 13759

Registration Number: NCT06686602

Locations: 🇺🇸
ConcertAI Database, Cambridge, Massachusetts, United States

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

Phase 2

Recruiting

Conditions: Advanced Solid Tumor
Metastatic Solid Tumors

Interventions: Drug: Raludotatug deruxtecan

First Posted Date: 2024-10-28

Last Posted Date: 2025-06-04

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 200

Registration Number: NCT06660654

Locations: 🇺🇸
Astera Cancer Care, East Brunswick, New Jersey, United States
🇺🇸
Women's Cancer Care Associates, Albany, New York, United States
🇺🇸
Clinical Research Alliance, Westbury, New York, United States

and more 11 locations

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

Phase 1

Recruiting

Conditions: Non-small Cell Lung Cancer
Lung Cancer

Interventions: Drug: valemetostat tosylate
Drug: pembrolizumab

First Posted Date: 2024-10-16

Last Posted Date: 2024-11-14

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 137

Registration Number: NCT06644768

Locations: 🇺🇸
University of California San Diego (Ucsd)-Moores Cancer Center, La Jolla, California, United States
🇺🇸
California Research Institute, Los Angeles, California, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 38 locations

First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors
Sarcoma

Interventions: Drug: DS-2243a

First Posted Date: 2024-10-16

Last Posted Date: 2025-05-09

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 150

Registration Number: NCT06644755

Locations: 🇧🇪
UZ Leuven Europe Leuven, Leuven, Belgium
🇫🇷
Centre Leon Berard, Lyon, France
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Phase 3

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Ifinatamab deruxtecan
Drug: Docetaxel
Drug: Paclitaxel
Drug: Irinotecan hydrochloride (HCl)

First Posted Date: 2024-10-16

Last Posted Date: 2025-06-08

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 510

Registration Number: NCT06644781

Locations: 🇯🇵
Hiroshima University Hospital, Hiroshima-shi, Japan
🇯🇵
Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe-shi, Japan
🇯🇵
Shizuoka Cancer Center, Nagaizumi-chō, Japan

and more 12 locations

A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments

Active, not recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Other: No drug

First Posted Date: 2024-09-27

Last Posted Date: 2025-05-15

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 1200

Registration Number: NCT06617390

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy